



Press Release, 31 May 2012

Number of shares and votes in Medivir

The number of shares and votes in Medivir has changed as a result of the exercise of employee stock options.

Today, the last trading day of the month, there are in total 31 260 027 shares and 37 200 027 votes in the company.

Stockholm, May 31, 2012
Medivir AB (publ)

For further information, please contact:

Rein Piir, EVP Corporate Affairs & IR, Medivir
Office line +46 8 440 6550 or Mobile +46 708 537292

Medivir is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 8.00 am CET on May 31, 2012.

About Medivir

Medivir is an emerging research-based pharmaceutical company focused on the development of high-value treatments for infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company's key pipeline asset is TMC435, a novel protease inhibitor in phase III clinical development for hepatitis C that is being developed in collaboration with Janssen Pharmaceuticals.

In June 2011, Medivir acquired the specialty pharmaceutical company BioPhausia to ensure timely commercialisation of TMC435 in the Nordic markets, once approved.

Medivir's first product, the unique cold sore product Xerese[®]/Xerclear[®], was launched on the US market in 2011. Xerese[®]/Xerclear[®], which has been approved in both the US and Europe, is being launched in collaboration with GlaxoSmithKline to be sold OTC in Europe, Japan and Russia. Rights in North America, Canada and Mexico were sold to Meda AB in June 2011. Medivir has retained the Rx rights for Xerclear[®] in Sweden and Finland.

For more information about Medivir, please visit the Company's website: www.medivir.com